Business
Arcutis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Achieved net revenues of $3.0 million for ZORYVE® (roflumilast) cream 0.3% in the first full quarter since the August 2022 launch, driven by continued unit
About this update from Arcutis Biotherapeutics, Inc.
[{"type":"text","content":"Achieved net revenues of $3.0 million for ZORYVE® (roflumilast) cream 0.3% in the first full quarter since the August 2022 launch, driven by continued unit demand growthSecured expanded commercial payer coverage for ZORYVE in plaque psoriasis with the second of the top three pharmacy benefit managers in the U.S., as well as an additional national health planAnnounced positive topline results from INTEGUMENT-1 and INTEGUMENT-2, the two pivotal Phase 3 trials in individuals with atopic dermatitis ages 6 years and olderSubmitted New Drug Application (NDA) for roflumilast foam for the treatment of seborrheic dermatitis in adults and adolescentsEnrolled first patient in Phase 1b alopecia areata study evaluating ARQ-255Strong financial position with approximately $410 million in cash, cash equivalents, and marketable securities WESTLAKE VILLAGE, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported financial results for the quarter and year ended December 31, 2022, and provided a business update. “Arcutis' execution in 2022 was extraordinary, setting us up very well for 2023 and beyond. We are well on our way towards building one of the industry's leading medical dermatology companies focused on long-term growth from our broad, innovative pipeline,” said Frank Watanabe, Arcutis’ President and Chief Executive Officer. “From June to December last year, we delivered four successful pivotal Phase 3 trial readouts, secured an on-time approval for ZORYVE in plaque psoriasis, and raised nearly $300 million to bolster a strong balance sheet. The momentum around the ZORYVE psoriasis launch continues to build, with confirmatory feedback on our differentiated product profile and access strategy setting the foundation for commercial success in psoriasis as well as our next three indications.” Program Updates / Key Milestones ZORYVE (roflumilast) cream - a highly potent and selective phosphodiesterase-4 (PDE4) inhibitor in a once-daily cream formulation, approved in the U.S. for the treatment of plaque psoriasis and under development for atopic dermatitis The launch of ZORYVE continues to build momentum, with over 20,000 prescriptions written by over 4,000 unique prescribers since ...